CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 266 enrolled
Drug / intervention
Aripiprazole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04030143
NCT04030143Phase 2Completed

A Phase 1b, Open-label, Multiple-dose, Randomized, Parallel-arm, Safety, Tolerability, and Pharmacokinetic Trial of Aripiprazole Intramuscular Depot Administered in the Gluteal Muscle in Adult Subjects With Schizophrenia or Bipolar I Disorder

Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted Jul 23, 2019·Updated Nov 18, 2023

In Brief

A Phase 2 clinical trial evaluating Aripiprazole for Schizophrenia and Bipolar I Disorder. Completed, enrolled 266 participants across 19 sites.

Detailed Summary

The purpose of this trial is to determine the safety and tolerability of multiple-dose administrations of aripiprazole, to establish the similarity of aripiprazole concentrations on the last day of the dosing interval following the final administration of aripiprazole into the gluteal muscle site, and to establish the similarity of aripiprazole exposure over the dosing interval following the administration of aripiprazole into the gluteal muscle site in adult participants with schizophrenia or bipolar I disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedJul 23, 2019
Enrollment StartAug 1, 2019
Primary CompletionJul 8, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.9 years ago

Interventions

Aripiprazoledrug

Administered as an intramuscular (IM) depot injection.

Aripiprazoledrug

Administered as an IM depot injection.